BACKGROUND: Although antigen processing and presentation of allergens to CD4(+)T lymphocytes are key events in the pathophysiology of allergic disorders, they still remain poorly understood. OBJECTIVE: To investigate allergen processing and presentation by dendritic cells using the major birch pollen allergen Bet v 1 as a model. METHODS: Endolysosomal extracts of dendritic cells derived from patients with birch pollen allergy were used to digest Bet v 1. Dendritic cells were pulsed with Bet v 1, and peptides were eluted from MHC class II molecules. Peptides obtained by either approach were sequenced by tandem mass spectrometry. Bet v 1-specific T-cell cultures were stimulated with HLA-DR-eluted Bet v 1-derived peptides. Bet v 1-specific T-cell lines were generated from each patient and analyzed for epitope recognition. RESULTS: A high proportion of Bet v 1 remained intact for a long period of endolysosomal degradation. The peptides that appeared early in the degradation process contained frequently recognized T-cell epitopes. Bet v 1-derived peptides eluted from MHC class II molecules corresponded to those generated by endolysosomal degradation, matched known T-cell epitopes, and showed T cell-activating capacity. The Bet v 1-specific T-cell line of each individual harbored T cells reactive with peptides located within the MHC class II-eluted Bet v 1-derived sequences demonstrating their occurrence in vivo. CONCLUSION: We report for the first time how epitopes of allergens are generated and selected for presentation to T lymphocytes. The limited susceptibility of Bet v 1 to endolysosomal processing might contribute to its high allergenic potential.
BACKGROUND: Although antigen processing and presentation of allergens to CD4(+)T lymphocytes are key events in the pathophysiology of allergic disorders, they still remain poorly understood. OBJECTIVE: To investigate allergen processing and presentation by dendritic cells using the major birch pollen allergen Bet v 1 as a model. METHODS: Endolysosomal extracts of dendritic cells derived from patients with birch pollen allergy were used to digest Bet v 1. Dendritic cells were pulsed with Bet v 1, and peptides were eluted from MHC class II molecules. Peptides obtained by either approach were sequenced by tandem mass spectrometry. Bet v 1-specific T-cell cultures were stimulated with HLA-DR-eluted Bet v 1-derived peptides. Bet v 1-specific T-cell lines were generated from each patient and analyzed for epitope recognition. RESULTS: A high proportion of Bet v 1 remained intact for a long period of endolysosomal degradation. The peptides that appeared early in the degradation process contained frequently recognized T-cell epitopes. Bet v 1-derived peptides eluted from MHC class II molecules corresponded to those generated by endolysosomal degradation, matched known T-cell epitopes, and showed T cell-activating capacity. The Bet v 1-specific T-cell line of each individual harbored T cells reactive with peptides located within the MHC class II-eluted Bet v 1-derived sequences demonstrating their occurrence in vivo. CONCLUSION: We report for the first time how epitopes of allergens are generated and selected for presentation to T lymphocytes. The limited susceptibility of Bet v 1 to endolysosomal processing might contribute to its high allergenic potential.
Authors: Tingfeng Li; N Kalaya Steede; Hong-Nam P Nguyen; Lucy C Freytag; James B McLachlan; Ramgopal R Mettu; James E Robinson; Samuel J Landry Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Simon D van Haren; Eszter Herczenik; Anja ten Brinke; Koen Mertens; Jan Voorberg; Alexander B Meijer Journal: Mol Cell Proteomics Date: 2011-04-05 Impact factor: 5.911
Authors: Carla Oseroff; Lars H Christensen; Luise Westernberg; John Pham; Jerome Lane; Sinu Paul; Jason Greenbaum; Thomas Stranzl; Gitte Lund; Ilka Hoof; Jens Holm; Peter A Würtzen; Kåre H Meno; April Frazier; Veronique Schulten; Peter S Andersen; Bjoern Peters; Alessandro Sette Journal: Clin Exp Allergy Date: 2016-11-07 Impact factor: 5.018
Authors: Michael Wallner; Michael Hauser; Martin Himly; Nadja Zaborsky; Sonja Mutschlechner; Andrea Harrer; Claudia Asam; Ulrike Pichler; Ronald van Ree; Peter Briza; Josef Thalhamer; Barbara Bohle; Gernot Achatz; Fatima Ferreira Journal: J Allergy Clin Immunol Date: 2011-03-21 Impact factor: 10.793
Authors: Matthias Egger; Alexander Jürets; Michael Wallner; Peter Briza; Silke Ruzek; Stefan Hainzl; Ulrike Pichler; Claudia Kitzmüller; Barbara Bohle; Christian G Huber; Fátima Ferreira Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240
Authors: Bernhard Knapp; Gottfried Fischer; Dries Van Hemelen; Ingrid Fae; Bernard Maillere; Christof Ebner; Wolfgang Schreiner; Barbara Bohle; Beatrice Jahn-Schmid Journal: BMC Immunol Date: 2012-08-08 Impact factor: 3.615